Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) reached a new 52-week low on Thursday. The company traded as low as GBX 34 and last traded at GBX 38, with a volume of 36127 shares traded. The stock had previously closed at GBX 36.50.
Faron Pharmaceuticals Oy Price Performance
The firm has a 50 day moving average of GBX 38.62 and a 200-day moving average of GBX 41.67. The company has a current ratio of 2.40, a quick ratio of 1.09 and a debt-to-equity ratio of 154.15. The company has a market cap of £71.62 million, a P/E ratio of -3.06 and a beta of 1.12.
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Read More
- Five stocks we like better than Faron Pharmaceuticals Oy
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
